A House subcommittee voted unanimously Thursday to send a bill intended to stop sham citizen petitions from clogging the FDA’s approval process for generic drugs under the section 505 pathway to the full Energy and Commerce Committee.
A House subcommittee voted unanimously Thursday to send a bill intended to stop sham citizen petitions from clogging the FDA’s approval process for generic drugs under the section 505 pathway to the full Energy and Commerce Committee.
The bipartisan bill, HR 2387, the Stop the Overuse of Petitions and Get Affordable Medicines to Enter Soon (STOP GAMES) Act of 2019, was introduced last spring by Representatives Andy Levin, D-Michigan, and Francis Rooney, R-Florida.
Citizen petitions are an avenue for any interested party to ask the FDA commissioner to change agency regulations or take—or refrain from taking—an administrative action. In the case of drug makers, such requests may include asking the FDA not to approve a generic or biosimilar product unless certain conditions are met.
Citizen petitions have nonetheless been the subject of controversy, as they require significant time and resources for the FDA to address. Among many stakeholders, there exists a consensus that brand-name drug makers could (and sometimes do) use these petitions to forestall competition from generic or biosimilar drugs.
In September, the FDA released final guidance to determine if citizen petitions are abusive.
If the bill becomes law, it would codify the FDA’s intent. It would allow the FDA to quickly reject a citizen petition submitted with the aim to stall a generic drug’s approval. It directs the HHS secretary to report such citizen petitions to the Federal Trade Commission and requires drug manufacturers to file a petition within 60 days of receiving actionable information. The bill also directs the FDA to report additional information to Congress, including: time and resources spent on each petition; timing of petitions relative to patent expiration; and any delay in approval of a competing generic drug caused by such petition.
America’s Health Insurance Plans (AHIP) submitted testimony on behalf of its member payer organizations, saying that while the FDA’s “petition process provides an opportunity to raise legitimate concerns about the safety and effectiveness of new drugs, it has also been exploited to delay or prevent the availability of more affordable generic drugs and biosimilars. This legislation takes important steps to curb abuses in the citizen petition process and remove barriers to the generic drugs that Americans need and deserve.”
Supporters of the bill say certain drug makers have abused the petition process to slow approvals and maintain monopolies.
However, on the other side of Congress this week, a bill called the Affordable Prescriptions for Patients Act did not advance, with Senator John Cornyn, R-Texas, accusing Senate Minority Leader Chuck Schumer, D-New York, of blocking the bill.
Cornyn and Senator Richard Blumenthal, D-Connecticut, introduced the bill, which aims to prevent patent thickets and product hopping, last spring. It has since gained other sponsors.
Schumer said the bill does not go far enough, according to a report, which also said that Schumer noted that Senate Majority Leader Mitch McConnell, R-Kentucky, had not scheduled any votes on any bills aimed at drug prices.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.